Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04314934Phase 2Completed

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

Role: collaborator

NCT04304482Phase 2Completed

ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome

Role: collaborator

NCT04575259Phase 2Completed

OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Role: collaborator

NCT03790709Phase 2Completed

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

Role: collaborator

NCT04442945Phase 1Completed

Phase 1 Study of ANAVEX3-71

Role: collaborator

All 5 trials loaded